Abstract | RATIONALE: AIMS: DESIGN:
Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) is a randomized, double-blind, event-driven trial and will include an estimated 13,600 participants randomized in 33 countries worldwide to collect 844 primary events. STUDY OUTCOMES: The primary endpoint is the composite of stroke (ischemic or hemorrhagic), myocardial infarction, and death. Time to the first primary endpoint will be compared in the treatment groups during 90-day follow-up, with major hemorrhage serving as the primary safety endpoint. Participants will be followed for an additional 30 days after the randomized treatment period. DISCUSSION:
|
Authors | S Claiborne Johnston, Pierre Amarenco, Gregory W Albers, Hans Denison, J Donald Easton, Peter Held, Jenny Jonasson, Kazuo Minematsu, Carlos A Molina, Lawrence K S Wong |
Journal | International journal of stroke : official journal of the International Stroke Society
(Int J Stroke)
Vol. 10
Issue 8
Pg. 1304-8
(Dec 2015)
ISSN: 1747-4949 [Electronic] United States |
PMID | 26311628
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 The Authors. International Journal of Stroke published by John Wiley & Sons Ltd on behalf of World Stroke Organization. |
Chemical References |
- Fibrinolytic Agents
- Purinergic P2Y Receptor Antagonists
- Ticagrelor
- Adenosine
- Aspirin
|
Topics |
- Adenosine
(analogs & derivatives, therapeutic use)
- Aspirin
(therapeutic use)
- Double-Blind Method
- Fibrinolytic Agents
(therapeutic use)
- Follow-Up Studies
- Humans
- Internationality
- Ischemic Attack, Transient
(drug therapy, mortality)
- Myocardial Infarction
(drug therapy, mortality)
- Purinergic P2Y Receptor Antagonists
(therapeutic use)
- Research Design
- Ticagrelor
- Treatment Outcome
|